

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human IL-17 RA/IL-17 R in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse (m) IL-17 R, rIL-17B R, or recombinant human IL-17B R is observed. In Western blots, no cross-reactivity with rIL-17 R is observed
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 133617
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human IL-17 RA/IL-17 R Leu33-Trp320 Accession # Q96F46
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 µg/mL	Recombinant Human IL-17 RA/IL-17 R Fc Chimera (Catalog # 177-IR)
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	K562 human chronic myelogenous leukemia cell line
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
<b>Neutralization</b>	Measured by its ability to neutralize IL-17/IL-17A-induced CXCL1/GRO $\alpha$ secretion in the HT-29 human colon adenocarcinoma cell line. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.4-2 µg/mL in the presence of 40 ng/mL Recombinant Human IL-17/IL-17A.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Interleukin 17 (also known as CTLA-8) is a T cell-expressed pleotropic cytokine. IL-17 binds to IL-17 receptor (IL-17 R) which shares no homology with any known family of receptors. While the expression of IL-17 is restricted to activated T cells, the IL-17 R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested. Human IL-17 R is a 120 kDa, 866 amino acid (aa) type I membrane glycoprotein with a 293 aa extracellular domain, a 21 aa carboxy-proximal transmembrane domain, and a 525 aa cytoplasmic tail. Within the ECD, human IL-17 R shares 72% aa sequence identity with mouse and rat IL-17 R. The signaling events of IL-17 includes activation of NF- $\kappa$ B and JNK, and require TNF receptor-associated factors 6 (TRAF6) in the signaling pathway.

## References:

1. Yao, Z. *et al.* (1997) Cytokine **9**:794.
2. Schwander, R. *et al.* (2000) J. Exp. Med. **191**:1233.